Rashmi Kanagal-Shamanna, MD, Discusses Optical Genome Mapping
By Leah Sherwood, Rashmi Kanagal-Shamanna, MD - Last Updated: February 13, 2023Rashmi Kanagal-Shamanna, MD, of the MD Anderson Cancer Center, discusses the optical genome mapping platform and the clinical implications the technology will have for patients with acute myeloid leukemia and myelodysplastic syndromes.
Advertisement
Related Posts
The 60-day mortality rate was around twice as high in patients with KMT2A rearrangement.
While NPM1 mutations impacted CR rates, they had “no impact” on RFS and OS after each line of salvage therapy.
Revumenib is a potent, selective oral inhibitor of interaction between menin and KMT2A.
A new study suggests CR with MRD negativity should be the “key objective" of high- and low-intensity therapy for AML.
The FDA has approved an Investigational New Drug application for EP0042, a dual FLT-3 and aurora kinase inhibitor.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
670 Madison Ave.
Manalapan, NJ 07726